BRIDGEWATER, N.J., Sept. 3, 2019 /PRNewswire/ -- Insmed Incorporated
(Nasdaq: INSM), a global biopharmaceutical company on a mission to
transform the lives of patients with serious and rare diseases,
today announced that management will present at the following
investor conferences:
- The H.C. Wainwright 21st Annual Global Investment
Conference in New York, NY on
Tuesday, September 10, 2019 at
8:20 a.m. ET.
- The Morgan Stanley 17th Annual Global Healthcare
Conference in New York, NY on
Tuesday, September 10, 2019 at
5:15 p.m. ET.
The presentations will be webcast live and can be accessed by
visiting the investor relations section of the company's website at
www.insmed.com. The webcasts will be archived for a period of 90
days following the conclusion of each live event.
About Insmed
Insmed Incorporated is a global biopharmaceutical company on a
mission to transform the lives of patients with serious and rare
diseases. Insmed's first commercial product is ARIKAYCE®
(amikacin liposome inhalation suspension), which is approved in
the United States for the
treatment of Mycobacterium avium complex (MAC) lung disease as part
of a combination antibacterial drug regimen for adult patients with
limited or no alternative treatment options. MAC lung disease is a
rare and often chronic infection that can cause irreversible lung
damage and can be fatal. Insmed's earlier-stage clinical pipeline
includes INS1007, a novel oral reversible inhibitor of dipeptidyl
peptidase 1 with therapeutic potential in non-cystic fibrosis
bronchiectasis and other inflammatory diseases, and INS1009, an
inhaled formulation of a treprostinil prodrug that may offer a
differentiated product profile for rare pulmonary disorders,
including pulmonary arterial hypertension. For more information,
visit www.insmed.com.
Contact:
Blaine Davis
Head of Investor Relations and Corporate Communications
Insmed Incorporated
(908) 947-2841
blaine.davis@insmed.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/insmed-to-present-at-two-september-conferences-300909800.html
SOURCE Insmed Incorporated